Michael Douglas
@michaeldouglasms.bsky.social
Program Manager, Scientist and Researcher in Personalized Genomic Medicine, lover of travel and wine.
US payers, providers & stakeholders see payer role in genomic testing implementation as feasible. Findings inform broad healthcare efforts & precision oncology professionals shaping policy. See TRANSPERS latest publication. pubmed.ncbi.nlm.nih.gov/40020207/
March 2, 2025 at 7:36 PM
US payers, providers & stakeholders see payer role in genomic testing implementation as feasible. Findings inform broad healthcare efforts & precision oncology professionals shaping policy. See TRANSPERS latest publication. pubmed.ncbi.nlm.nih.gov/40020207/
Join Dr. Oni-Orisan's @UCSF team as a postdoc in biostatistics, pharmacogenomics, cardiology & precision medicine. Analyze large datasets of EHR, genomic data, drug regimens & clinical outcomes. Email CV & research interests to Michael.Douglas@ucsf.edu @akinyemi_OO @IHG_at_UCSF
November 26, 2024 at 10:52 PM
Join Dr. Oni-Orisan's @UCSF team as a postdoc in biostatistics, pharmacogenomics, cardiology & precision medicine. Analyze large datasets of EHR, genomic data, drug regimens & clinical outcomes. Email CV & research interests to Michael.Douglas@ucsf.edu @akinyemi_OO @IHG_at_UCSF
Our preliminary findings from 10 interviews w/ Geriatricians found that most are aware of ApoE testing but their knowledge and comfort level counseling patients varies. Most do not order it and their conversations are around utility of testing for patients and family members. 5/7
November 26, 2024 at 10:52 PM
Our preliminary findings from 10 interviews w/ Geriatricians found that most are aware of ApoE testing but their knowledge and comfort level counseling patients varies. Most do not order it and their conversations are around utility of testing for patients and family members. 5/7
With disease-modifying therapies on the horizon, should you undergo genetic testing for early detection of Alzheimer’s Disease? Will your insurance cover? Will your doctor know what to do? Is there economic value in doing so? We set out to explore further. #DementiaDay2021 1/7
November 26, 2024 at 10:52 PM
With disease-modifying therapies on the horizon, should you undergo genetic testing for early detection of Alzheimer’s Disease? Will your insurance cover? Will your doctor know what to do? Is there economic value in doing so? We set out to explore further. #DementiaDay2021 1/7
The March 2021 TRANSPERS Newsletter is out today. The issues highlights some of our work from this past Fall and Winter. Follow us on Twitter @UCSF_TRANSPERS https://pharm.ucsf.edu/transpers/news/transpers-march-2021-newsletter
November 26, 2024 at 10:52 PM
The March 2021 TRANSPERS Newsletter is out today. The issues highlights some of our work from this past Fall and Winter. Follow us on Twitter @UCSF_TRANSPERS https://pharm.ucsf.edu/transpers/news/transpers-march-2021-newsletter
Special congratulations to @22Kathryn11 and @stacywgray on our most recent publication! Private Payer and Medicare Coverage for Circulating Tumor DNA Testing: A Historical Analysis of Coverage Policies From 2015 to 2019 https://jnccn.org/view/journals/jnccn/18/7/article-p866.xml#.XwTRuLqH6oc.tw...
November 26, 2024 at 10:52 PM
Special congratulations to @22Kathryn11 and @stacywgray on our most recent publication! Private Payer and Medicare Coverage for Circulating Tumor DNA Testing: A Historical Analysis of Coverage Policies From 2015 to 2019 https://jnccn.org/view/journals/jnccn/18/7/article-p866.xml#.XwTRuLqH6oc.tw...
Our paper in a VIH Theme section uses temporal analyses to assess U.S. private payer coverage for Tumor Sequencing, which reveals important trends in coverage decisions and informs economic and affordability assessments. #GlobalGenomicsEconomics https://www.valueinhealthjournal.com/article/S1098...
November 26, 2024 at 10:52 PM
Our paper in a VIH Theme section uses temporal analyses to assess U.S. private payer coverage for Tumor Sequencing, which reveals important trends in coverage decisions and informs economic and affordability assessments. #GlobalGenomicsEconomics https://www.valueinhealthjournal.com/article/S1098...
Our paper in a VIH Theme section examines improving use of Real World Evidence for payer decision-making involves strategies to overcome data, methodologic and policy challenges are advanced by coordinating with stakeholders. #GlobalGenomicsEconomics https://www.valueinhealthjournal.com/article/S...
November 26, 2024 at 10:52 PM
Our paper in a VIH Theme section examines improving use of Real World Evidence for payer decision-making involves strategies to overcome data, methodologic and policy challenges are advanced by coordinating with stakeholders. #GlobalGenomicsEconomics https://www.valueinhealthjournal.com/article/S...